Go to the list of all blogs
Allana's Avatar
published in Blogs
Aug 31, 2026
Why Is Agilon Health (AGL) Stock Down -8.36% Today?

Why Is Agilon Health (AGL) Stock Down -8.36% Today?

Key Takeaways

  • AGL shares fell 8.36% to $84.80, down $7.74 from the prior session's close of $92.54.
  • The decline followed a fresh bearish analyst note that kept an Underweight rating while setting a price target below the stock's previous closing level.
  • Valuation concerns are compounding after an extraordinary 2026 rally that lifted the shares from single digits.
  • Medicare Advantage margin pressures heading into 2027 remain a key overhang on the value-based care business.
  • Traders are watching upcoming earnings, membership-growth trends, and any shift in sell-side sentiment.

Opening Summary

agilon health, inc. (AGL), a Medicare-centric healthcare services company that partners with community-based physician groups through its value-based care platform, saw its shares fall sharply in Monday's session. The stock declined 8.36% to $84.80, a drop of $7.74 from Friday's close of $92.54. The move extended a period of elevated volatility for a name that has traded in an unusually wide range this year. Markets attributed the selling primarily to renewed bearishness on valuation, with JPMorgan maintaining an Underweight rating while adjusting its price target to $85 — a level that, despite being raised from a prior $31, still implied meaningful downside from where the stock had been trading.

Analyst Action and Valuation Reset

The immediate catalyst was a research update from JPMorgan, which kept its Underweight rating on AGL while adjusting its price target to $85. Although the revised target represented a sharp increase from the firm's previous $31 objective, the new level remained below Friday's closing price of $92.54, signaling that the analyst still sees the risk/reward skewed to the downside. For a stock that has delivered one of the most dramatic recoveries in the healthcare sector this year, a target below the prevailing price was enough to trigger an outsized market reaction.

Valuation Concerns After a Massive Rally

The sell-off reflects deeper unease about how much of agilon health's turnaround is already priced in. After trading near its 52-week low in the single digits, AGL surged hundreds of percent in 2026 as the company reported stronger revenue, profitability gains, and an upbeat guidance update. That dramatic appreciation left the shares trading at a premium to peers and made them highly sensitive to any shift in expectations. Sell-side analysts have repeatedly flagged that recent outperformance in medical margin and adjusted EBITDA was driven partly by favorable prior-year development, revised risk-adjustment estimates, and unusually benign cost trends — factors that may be difficult to sustain at the same magnitude.

Medicare Advantage Overhang

Beyond the single analyst note, investors continue to weigh structural risks in the Medicare Advantage market. As insurers seek to protect margins heading into 2027, value-based care providers such as AGL face contract-renegotiation risk and potential pressure on reimbursement economics. Management has prioritized profitability over membership volume, which supports near-term margins but could constrain longer-term revenue growth. That trade-off has left the market questioning whether the company's improved fundamentals can keep pace with its elevated valuation.

Market Context and Trading Activity

The move was broad-based across the healthcare services complex, though AGL stood out as a notable decliner given its high beta and recent volatility. The stock has logged dozens of moves greater than 5% over the past year, so today's decline, while significant, fits a pattern of sharp single-session swings. The decline pushed the shares decisively below the $92 area that had acted as recent support, leaving the stock vulnerable to further technical selling if sentiment does not stabilize. Trading volume reflected the continuation of a relatively subdued trend seen in recent sessions rather than a dramatic surge in selling pressure.

What Comes Next for AGL

Investors will be watching agilon health's next earnings report for confirmation that recent margin improvements are durable rather than one-time in nature. Membership growth, medical cost trends, and updates on payer contract negotiations will be closely scrutinized. Analyst sentiment remains divided, with a mix of Hold, Sell, and a minority of bullish ratings, underscoring genuine disagreement about the company's path to consistent profitability. Risks include any disappointment in risk-adjustment outcomes, renewed pressure on Medicare Advantage economics, and continued valuation compression if the broader rally in high-momentum healthcare names loses steam.

Trending AI Robots

For traders seeking a data-driven approach to volatile names like AGL, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing automated strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the top performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches aligned with their own objectives. Explore the Trending AI Robots page to see which automated strategies are adapting best to today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AGL

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


AGL's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for AGL turned positive on August 18, 2026. Looking at past instances where AGL's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where AGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AGL advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .

AGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AGL as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

AGL moved below its 50-day moving average on August 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AGL crossed bearishly below the 50-day moving average on July 31, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AGL entered a downward trend on August 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.831) is normal, around the industry mean (238.659). P/E Ratio (0.000) is within average values for comparable stocks, (131.955). AGL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.716). AGL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.014). P/S Ratio (0.262) is also within normal values, averaging (2.668).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 4.8B. The market cap for tickers in the group ranges from 48.5K to 90.46B. HCA holds the highest valuation in this group at 90.46B. The lowest valued company is BYZN at 48.5K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -3%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 24%. BMGL experienced the highest price growth at 12%, while NIVF experienced the biggest fall at -27%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was -15%. For the same stocks of the Industry, the average monthly volume growth was -20% and the average quarterly volume growth was 54%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 48
Price Growth Rating: 50
SMR Rating: 65
Profit Risk Rating: 88
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
AGL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry HospitalNursingManagement

Profile
Details
Industry
N/A
Address
6210 East Highway 290
Phone
+1 562 256-3800
Employees
1117
Web
https://www.agilonhealth.com
Interact to see
Advertisement
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.
Coherent Corp (COHR) has surged 200%+ over the past year and 35% YTD, fueled by AI datacenter demand and strong Q2 fiscal 2026 results (17% YoY revenue growth). QUALCOMM Incorporated (QCOM) trades at a reasonable PE of 29x with 15% YTD gains, but memory shortages have constrained handset sales, partially offset by growth in data center chips. Taiwan Semiconductor Manufacturing Company Limited (TSM) leads with 96% one-year returns and 28% YTD, supported by record AI chip sales and projected 53.8% quarterly earnings growth.
RIME (Algorhythm Holdings Inc.) is up more than 24% today mainly because its SemiCab unit landed a high‑profile pilot with Coca‑Cola’s largest bottling partner in India, reinforcing bullish sentiment around its AI freight platform and sparking aggressive retail and momentum buying in a thinly traded penny stock.
GDDY (GoDaddy) is down more than 17% today because its 2026 revenue outlook and near‑term sales guidance came in below Wall Street expectations, reinforcing worries about slowing growth and intense AI‑driven competition even though Q4 2025 headline results were solid.
For the first half of fiscal 2026, organic net sales and adjusted EPS both declined about 3% year over year and missed analyst expectations, with U.S. spirits and Chinese white spirits particularly weak. Management cut full‑year 2026 guidance again, now expecting organic sales to fall 2–3% and organic operating profit to be flat to up only low single digits, versus a prior outlook of flat to slightly down sales and low‑ to mid‑single‑digit profit growth.
DRVN (Driven Brands) is down more than 36% today because the company disclosed serious errors in its past financial statements, is delaying its Q4 2025 earnings release, and will have to restate results for the last two fiscal years, which shattered investor confidence and raised concerns about leverage and profitability.
Q4 2025 revenue was strong at about 257–258 million (up roughly 16% year over year and above forecasts), but adjusted EPS was 0.30 versus about 0.31–0.32 expected, and EBITDA of about 101–102 million was a touch below consensus.
Q4 2025 revenue was about 392 million, roughly 10–20% below consensus (around 430–440 million), and EPS came in at −0.44−0.44 versus forecasts near −0.27−0.27 to −0.32−0.32, a more than 60% negative surprise. Results were hit by a roughly 170 million non‑cash impairment plus weaker realized pricing and volumes, driving a large net loss in the quarter despite strong full‑year EBITDA and free cash flow.
AXON surged approximately +17.56% on February 25, 2026, closing at $520.18 versus the prior session's close of $442.51. The primary catalyst was a blowout Q4 2025 earnings report, with adjusted EPS of $2.15 crushing the consensus estimate of approximately $1.67.
CAVA shares surged approximately +25.01% on February 25, 2026, closing near $84.76, up from the prior session's close of $67.80. The primary catalyst was a better-than-expected Q4 fiscal 2025 earnings report, with EPS of $0.04 beating the $0.03 consensus estimate and revenue of ~$274.99M exceeding the $268.04M estimate.
ODD shares plunged approximately 49.21% on February 25, 2026, closing near $14.74, compared to the prior close of approximately $29.02. The primary catalyst was a shock Q1 2026 revenue warning: management guided for a roughly 30% year-over-year revenue decline due to a severe spike in customer acquisition costs (CAC).